Autonomic control of the heart: Going beyond the classical neurotransmitters

Experimental Physiology

Volumn 100, Issue 4, 2015, Pages 354-358

  Herring, Neil ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUROPEPTIDE Y; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS;

ACETYLCHOLINE RELEASE; ADRENERGIC STIMULATION; ARTICLE; BRADYCARDIA; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART FAILURE; HEART FUNCTION; HEART INFARCTION; HEART MUSCLE EXCITABILITY; HEART RATE; HUMAN; NERVE STIMULATOR; NONHUMAN; RECEPTOR BLOCKING; SYMPATHETIC NERVE; VAGUS NERVE STIMULATION; ANIMAL; AUTONOMIC NERVOUS SYSTEM; BIOLOGICAL MODEL; BLOOD PRESSURE; FEEDBACK SYSTEM; HEART; INNERVATION; METABOLISM; PHYSIOLOGY;

ANIMALS; AUTONOMIC NERVOUS SYSTEM; BLOOD PRESSURE; FEEDBACK, PHYSIOLOGICAL; HEART; HEART RATE; HUMANS; MODELS, CARDIOVASCULAR; MODELS, NEUROLOGICAL; NEUROTRANSMITTER AGENTS;

EID: 84925949846     PISSN: 09580670     EISSN: 1469445X     Source Type: Journal    
DOI: 10.1113/expphysiol.2014.080184     Document Type: Article

References (30)

1. Brack KE, Patel VH, Coote JH & Ng GA (2007). Nitric oxide mediates the vagal protective effect on ventricular fibrillation via effects on action potential duration restitution in the rabbit heart. J Physiol 583, 695-704.
2. Bryant SM & Hart G (1996). Effects of neuropeptide Y on L-type calcium current in guinea-pig ventricular myocytes. Br J Pharmacol 118, 1455-1460.
3. Burnstock G (1976). Do some nerve cells release more than one transmitter? Neuroscience 1, 239-248.
4. Burnstock G (2009). Autonomic neurotransmission: 60 years since Sir Henry Dale. Annu Rev Pharmacol Toxicol 49, 1-30.
5. Chottová Dvoráková M, Wiegand S, Pesta M, Slavíková J, Grau V, Reischig J, Kuncová J & Kummer W (2008). Expression of neuropeptide Y and its receptors Y1 and Y2 in the rat heart and its supplying autonomic and spinal sensory ganglia in experimentally induced diabetes. Neuroscience 151, 1016-1028.
6. CIBIS-II (1999). The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet 353, 9-13.
7. Cole CR, Blackstone EH, Pashkow FJ, Snader CE & Lauer MS (1999). Heart-rate recovery immediately after exercise as a predictor of mortality. N Engl J Med 341, 1351-1357.
8. Cuculi F, Herring N, De Caterina AR, Banning AP, Prendergast BD, Forfar JC, Choudhury RP, Channon KM & Kharbanda RK (2013). Relationship of plasma neuropeptide Y with angiographic, electrocardiographic and coronary physiology indices of reperfusion during ST elevation myocardial infarction. Heart 99, 1198-1203.
9. Eccles J (1976). From electrical to chemical transmission in the central nervous system. Notes Rec R Soc Lond 30, 219-230.
10. 1 receptor and PLC activation. J Mol Cell Cardiol 38, 205-212.
11. Heredia MP, Fernández-Velasco M, Benito G & Delgado C (2002). Neuropeptide Y increases 4-aminopyridine-sensitive transient outward potassium current in rat ventricular myocytes. Br J Pharmacol 135, 1701-1706.
12. Herring N, Cranley J, Lokale MN, Li D, Shanks J, Alston EN, Girard BM, Carter E, Parsons RL, Habecker BA & Paterson DJ (2012). The cardiac sympathetic co-transmitter galanin reduces acetylcholine release and vagal bradycardia: implications for neural control of cardiac excitability. J Mol Cell Cardiol 52, 667-676.
13. Herring N, Lokale MN, Danson EJ, Heaton DA & Paterson DJ (2008). Neuropeptide Y reduces acetylcholine release and vagal bradycardia via a Y2 receptor-mediated, protein kinase C-dependent pathway. J Mol Cell Cardiol 44, 477-485.
14. Hulting J, Sollevi A, Ullman B, Franco-Cereceda A & Lundberg JM (1990). Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure. Cardiovasc Res 24, 102-108.
15. ISIS-1 (1986). Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 2(8498), 57-66.
16. Jönsson-Rylander AC, Nordlander M, Svindland A & Ilebekk A (2003). Distribution of neuropeptide Y Y1 and Y2 receptors in the postmortem human heart. Peptides 24, 255-262.
17. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A & Schwartz PJ (1998). Baroreflex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Reflexes After Myocardial Infarction) Investigators. Lancet 351, 478-484.
18. Manabe N, Foldes FF, Töröcsik A, Nagashima H, Goldiner PL & Vizi ES (1991). Presynaptic interaction between vagal and sympathetic innervation in the heart: modulation of acetylcholine and noradrenaline release. J Auton Nerv Syst 32, 233-242.
19. Millar BC, Weis T, Piper HM, Weber M, Borchard U, McDermott BJ & Balasubramaniam A (1991). Positive and negative contractile effects of neuropeptide Y on ventricular cardiomyocytes. Am J Physiol Heart Circ Physiol 261, H1727-H1733.
20. Nash MP, Thornton JM, Sears CE, Varghese A, O'Neill M & Paterson DJ (2001). Ventricular activation during sympathetic imbalance and its computational reconstruction. J Appl Physiol 90, 287-298.
21. Potter E (1987). Presynaptic inhibition of cardiac vagal postganglionic nerves by neuropeptide Y. Neurosci Lett 83, 101-106.
22. Potter EK & McCloskey DI (1982). Peripheral inhibition of cardiac vagal action by sympathetic adrenergic stimulation. Proc Aust Soc Clin Exp Pharmacol 13, 99P.
23. Schwertfeger E, Klein T, Vonend O, Oberhauser V, Stegbauer J & Rump LC (2004). Neuropeptide Y inhibits acetylcholine release in human heart atrium by activation of Y2-receptors. Naunyn Schmiedebergs Arch Pharmacol 369, 455-461.
24. Shanks J, Manou-Stathopoulou S, Lu CJ, Li D, Paterson DJ & Herring N (2013). Cardiac sympathetic dysfunction in the prehypertensive spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 305, H980-H986.
25. 2 receptors at peripheral neuroeffector junctions. Br J Pharmacol 132, 861-868.
26. 2 receptors in modulation of cardiac parasympathetic neurotransmission. Regul Pept 103, 105-111.
27. Ullman B, Hulting J & Lundberg JM (1994). Prognostic value of plasma neuropeptide-Y in coronary care unit patients with and without acute myocardial infarction. Eur Heart J 15, 454-461.
28. Warner MR & Levy MN (1989). Inhibition of cardiac vagal effects by neurally released and exogenous neuropeptide Y. Circ Res 65, 1536-1546.
29. Warner MR, Senanayake PD, Ferrario CM & Levy MN (1991). Sympathetic stimulation-evoked overflow of norepinephrine and neuropeptide Y from the heart. Circ Res 69, 455-465.
30. Zhao HC, Liu ZB, Feng QL, Cui XL, Zhang CM & Wu BW (2006). [Effects of neuropeptide Y on ion channels in ventricular myocytes]. [Article in Chinese.] Sheng Li Xue Bao 58, 225-231.